Article
Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Nature reviews. Clinical oncology - 1 Jul 2016
Bible Keith C, Ryder Mabel
Abstract excerpt
Increased understanding of disease-specific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid cancer (MTC), and two agents (sorafenib and lenvatinib) for the treatment of radioactive- iodine refractory differentiated thyroid cancer (DTC) in both the USA and in the EU. The effects of these and other therapies on overall...
Topics
Join the communities discussing this publication.